Welcome to our dedicated page for Scilex Holding Company news (Ticker: SCLXW), a resource for investors and traders seeking the latest updates and insights on Scilex Holding Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scilex Holding Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scilex Holding Company's position in the market.
Scilex Holding Company (NASDAQ: SCLX) announced it will present a post-hoc analysis of their C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) from May 15-17, 2025 in Orlando, FL. The presentation will focus on interpreting the clinical meaningfulness of safety and efficacy data for SP-102 (SEMDEXA™) in treating lumbosacral radicular pain (LRP).
The poster presentation will be displayed throughout the meeting and will be accessible via the conference app. Additionally, it will be published in the Pain Physician journal. The research was conducted by a team of authors including Miller AM, Knezevic NN, Nalamachu S, and others.
Scilex Holding Company has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, trading under the symbol SCLX, met the crucial requirement of maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days, achieving this milestone on April 30, 2025.
As a result, Scilex will continue trading on the Nasdaq Capital Market under the symbols "SCLX" for common stock and "SCLXW" for public warrants. The company specializes in non-opioid pain management products, focusing on treatments for acute and chronic pain, along with neurodegenerative and cardiometabolic diseases.
This compliance achievement ensures Scilex maintains its position on the Nasdaq exchange, providing stability for this revenue-generating pharmaceutical company that develops and commercializes innovative pain management solutions.
FAQ
What is the current stock price of Scilex Holding Company (SCLXW)?
